The Proteomics Shared Resource provides analytical proteomics services to investigators in the VICC. Proteomics is the study of proteomes, which are the functional complements to genomes and which comprise diverse structural and catalytically functional multiprotein machines. Proteomics approaches offer new tools for the molecular analysis of cancer, the identification of therapeutic targets and mechanisms, and to identify markers for disease and therapeutic response. Analytical proteomics integrates tools for protein and peptide separations, MS analysis and bioinformatics to characterize proteomes and their component proteins. A unique feature of the Proteomics Shared Resource is the availability of all major proteomics analysis technologies, which offers exceptional flexibility in analytical approaches. It provides the following services: identification of proteins in both simple and complex multiprotein samples; analyses of protein modifications; analyses of differential protein expression and modification; development and implementation of methods to detect serum markers for tumors, therapeutic susceptibility and response; providing expertise and training in proteomics analysis and experimental design to VICC investigators; and facilitating the transition of new technology into proteomics research. Dr. Daniel C. Liebler serves as Scientific Director. A recent recruit to the VICC, he previously established a successful Proteomics Shared Resource in the Southeast Environmental Health Sciences Center and Arizona Cancer Center at the University of Arizona. The staff of the Shared Resource have specialized expertise that enable them assist investigators with coverage of a vast number of new technologies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA068485-13
Application #
7679664
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
13
Fiscal Year
2008
Total Cost
$461,108
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Goff, Laura W; Azad, Nilofer S; Stein, Stacey et al. (2018) Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer. Invest New Drugs :
Payton, Rebecca R; Rispoli, Louisa A; Nagle, Kimberly A et al. (2018) Mitochondrial-related consequences of heat stress exposure during bovine oocyte maturation persist in early embryo development. J Reprod Dev 64:243-251
Kovtun, Oleg; Tomlinson, Ian D; Bailey, Danielle M et al. (2018) Single Quantum Dot Tracking Illuminates Neuroscience at the Nanoscale. Chem Phys Lett 706:741-752
Schlegel, Cameron; Lapierre, Lynne A; Weis, Victoria G et al. (2018) Reversible deficits in apical transporter trafficking associated with deficiency in diacylglycerol acyltransferase. Traffic 19:879-892
Weigl, Korbinian; Thomsen, Hauke; Balavarca, Yesilda et al. (2018) Genetic Risk Score Is Associated With Prevalence of Advanced Neoplasms in a Colorectal Cancer Screening Population. Gastroenterology 155:88-98.e10
Johnson, Douglas B; Dahlman, Kimberly B (2018) Class Matters: Sensitivity of BRAF-Mutant Melanoma to MAPK Inhibition. Clin Cancer Res 24:6107-6109
Gilchuk, Pavlo; Kuzmina, Natalia; Ilinykh, Philipp A et al. (2018) Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. Immunity 49:363-374.e10
Hebron, Katie E; Li, Elizabeth Y; Arnold Egloff, Shanna A et al. (2018) Alternative splicing of ALCAM enables tunable regulation of cell-cell adhesion through differential proteolysis. Sci Rep 8:3208
Bangaru, Sandhya; Zhang, Heng; Gilchuk, Iuliia M et al. (2018) A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA. Nat Commun 9:2669
Means, Anna L; Freeman, Tanner J; Zhu, Jing et al. (2018) Epithelial Smad4 Deletion Up-Regulates Inflammation and Promotes Inflammation-Associated Cancer. Cell Mol Gastroenterol Hepatol 6:257-276

Showing the most recent 10 out of 2462 publications